Forcefield Therapeutics Launched With ‘Gamechanger’ Goal For Post-MI Therapy
Led By Ex-Sandoz Head Richard Francis
The newly launched biotech has a novel platform for discovering protective tissue factors and turning them into therapies,with heart failure prevention its first target.
You may also be interested in...
The German group is putting another €1.3bn into its Leaps by Bayer investment arm until the end of 2024 to support new companies that are "shifting core paradigms in the sectors of health and agriculture."
Some investors are shying away from early-stage gene therapy companies, but Richard Francis, CEO of kidney disease specialist Purespring, told Scrip that the pharmaceutical industry's appetite for the field has not waned and the best-equipped companies will flourish.
The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.